Mycenax Biotech
Mycenax Biotech Inc. provides biopharmaceutical services and solutions for drug development and production in Taiwan. The company's services include program evaluation/confirmation, cell line development and construction, process development technology platforms, drug characterization analysis, establishment of testing methods, and PIC/S GMP drug production. It offers plasmid DNA, antibody-drug c… Read more
Mycenax Biotech (4726) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.031x
Based on the latest financial reports, Mycenax Biotech (4726) has a cash flow conversion efficiency ratio of -0.031x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-50.35 Million) by net assets (NT$1.64 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mycenax Biotech - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Mycenax Biotech's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Mycenax Biotech Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mycenax Biotech ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Community Bank of the Bay
PINK:CBOBA
|
0.002x |
|
Logwin AG
XETRA:TGHN
|
0.123x |
|
First Mining Gold Corp
OTCQX:FFMGF
|
-0.006x |
|
Agenus Inc
NASDAQ:AGEN
|
0.052x |
|
GIFTEE INC.
F:84I
|
N/A |
|
Sebang
KO:004360
|
0.025x |
|
Iron Force Industrial Co Ltd
TW:2228
|
0.080x |
|
Lifezone Metals Limited
NYSE:LZM
|
-0.061x |
Annual Cash Flow Conversion Efficiency for Mycenax Biotech (2017–2024)
The table below shows the annual cash flow conversion efficiency of Mycenax Biotech from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$2.02 Billion | NT$-191.68 Million | -0.095x | -76.72% |
| 2023-12-31 | NT$2.45 Billion | NT$-131.18 Million | -0.054x | -10.84% |
| 2022-12-31 | NT$3.11 Billion | NT$-150.19 Million | -0.048x | +36.95% |
| 2021-12-31 | NT$1.91 Billion | NT$-146.23 Million | -0.077x | -153.36% |
| 2020-12-31 | NT$1.21 Billion | NT$174.17 Million | 0.144x | +212.55% |
| 2019-12-31 | NT$1.10 Billion | NT$-140.74 Million | -0.128x | +35.74% |
| 2018-12-31 | NT$907.01 Million | NT$-180.27 Million | -0.199x | -399.11% |
| 2017-12-31 | NT$1.14 Billion | NT$-45.55 Million | -0.040x | -- |